递归制药

最新新闻

• BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 评级变动
  Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $5
  \u5e02\u573a\u8d44\u8baf · 2025/6/18
• Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5.3
  \u5e02\u573a\u8d44\u8baf · 2026/8/17
• 评级变动
  BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $6
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $8
  \u5e02\u573a\u8d44\u8baf · 2025/5/7
• 评级变动
  BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $7
  \u5e02\u573a\u8d44\u8baf · 2025/12/9
• 评级变动
  JPMorgan has upgraded Recursion (RXRX.US) to an 'Overweight' rating, with its core pipeline candidate REC-4881 expected to become a blockbuster drug.
  Zhitong Finance · 2025/12/18
• 评级变动
  J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Cuts Target Price to $10
  \u5e02\u573a\u8d44\u8baf · 2026/4/30
• 评级变动
  J.P. Morgan Initiates Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Announces Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2025/12/17
• Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Recursion Pharmaceuticals (RXRX) and Contineum Therapeutics, Inc. Class A (CTNM)
  TipRanks · 2026/9/21
• 评级变动
  Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $5
  \u5e02\u573a\u8d44\u8baf · 2025/6/17
• J.P. Morgan Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/16
• 评级变动
  BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2025/8/6
• 评级变动
  Morgan Stanley Initiates Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Announces Target Price $5
  \u5e02\u573a\u8d44\u8baf · 2025/12/9
• 评级变动
  TD Cowen Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• 评级变动
  BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $7
  \u5e02\u573a\u8d44\u8baf · 2026/1/14
• 评级变动
  Needham Maintains Recursion Pharmaceuticals(RXRX.US) With Buy Rating, Maintains Target Price $8
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Maintains Target Price $6
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• 评级变动
  TR | OpenAI - 4o Initiates Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Announces Target Price $6
  \u5e02\u573a\u8d44\u8baf · 2025/8/6
• 评级变动
  Morgan Stanley Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Raises Target Price to $5.5
  \u5e02\u573a\u8d44\u8baf · 2026/5/14

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。